Abstract
Objectives Alemtuzumab is a recommended treatment for highly active disease (HAD) patients by the AAN. We aim to conduct a long-term follow-up of patients treated with Lemtrada for ≥9 years, evaluating various clinical efficacy, safety & neuroradiological parameters.
Methods We conducted a retrospective analysis of adult MS patients who received Alemtuzumab between 2014 and 2024. Demographics, treatment history, and clinical outcomes were collected from electronic medical records. The patients were called for the latest follow-up in 2024, where their current data, including EDSS, was recorded. Relapse rates, treatment-related adverse events, and Serial MRI scans were analysed for changes in lesion burden and brain volume loss (BVL). Processing speed was tested using Symbol Digit Modalities Testing.
Results We had 67 patients (31M, 36F). Data collection is complete but the Analysis and results will be ready in March 2024. Clinical outcomes include annualised relapse rate, patients requiring extra dose(s) of Lemtrada/other DMTs, change in EDSS, 6-month confirmed disability worsening, 6-month confirmed disability improvement, cognitive function and side effects of Lemtrada. MRI outcomes include disease activity and BVL. A correlation with time is studied for side effects, relapses, and BVL.
Conclusion With our extended follow-up, we hope to answer questions such as: does alemtuzumab have sustained efficacy in reducing Progression independent of relapses (PIRA)? There have been many new therapies, and Lemtrada has its limitations in the form of side effects. However, its ease of administration and high efficacy are significant benefits. Does it stand a chance as the most effective therapy.
